NEW OPPORTUNITIES OF TREATMENT OF DIFFERENT TYPES OF JUVENILE ARTHRITIS WITH MONOCLONAL ANTIBODIES TO THE INTERLEUKIN 6 RECEPTOR

The article observes the data on the role of interleukin (IL) 6 in pathogenesis of rheumatoid arthritis and treatment of rheumatoid arthritis and different types of juvenile arthritis with blocker IL 6 receptor (tocilizumab). The data on multicenter open-labeled and double-blinded randomized studies...

Full description

Bibliographic Details
Main Authors: E.I. Alexeeva, R.V. Denisova, S.I. Valieva, T.M. Bzarova, A.O. Lisitsyn
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2010-01-01
Series:Вопросы современной педиатрии
Online Access:https://vsp.spr-journal.ru/jour/article/view/828
Description
Summary:The article observes the data on the role of interleukin (IL) 6 in pathogenesis of rheumatoid arthritis and treatment of rheumatoid arthritis and different types of juvenile arthritis with blocker IL 6 receptor (tocilizumab). The data on multicenter open-labeled and double-blinded randomized studies on effectiveness and safety of tocilizumab are reviewed. The results of studies showed high effectiveness and safety of tocilizumab in treatment of rheumatoid arthritis and juvenile arthritis. Key words: children, rheumatoid arthritis, juvenile arthritis, interleukin 6, treatment, tocilizumab.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):52-61)
ISSN:1682-5527
1682-5535